Cognito Therapeutics Secures $105 Million Series C to Advance At-Home Alzheimer's Device Toward 2027 Launch
Key Insights
Cognito Therapeutics (search) closed an oversubscribed $105 million Series C round led by Morningside Ventures (search) to support pivotal data readout and regulatory submission for Spectris, its investigational at-home Alzheimer's therapy.
Spectris is a non-invasive device delivering coordinated visual and auditory stimulation through gamma frequency light and sound for one hour daily, designed to preserve cognition and daily function in Alzheimer's patients.
The company's fully enrolled HOPE pivotal study expects top-line data later this year, with commercial launch preparation targeting anticipated 2027 market entry.
Cognito Therapeutics (search) has closed an oversubscribed $105 million Series C funding round to advance its investigational at-home Alzheimer's therapy toward regulatory approval and commercial launch, targeting a 2027 market entry. The round was led by Morningside Ventures (search), IAG Capital Partners (search), and Starbloom Capital (search), with participation from new investors including Apollo Health Ventures (search) and Benvolio Group (search).
The Cambridge-based company, founded nearly a decade ago, has now raised $233 million to date as it develops Spectris, a novel sensory stimulus device for Alzheimer's disease treatment.
Device Technology and Mechanism
Spectris is a non-invasive device that resembles sunglasses connected to over-ear headphones, delivering coordinated visual and auditory stimulation through the brain's natural sensory pathways. Based on research from the Massachusetts Institute of Technology, the device beams patients with gamma frequency light and sound for one hour daily, with the goal of preserving cognition, daily function, and brain structure in Alzheimer's patients.
The stimulus is designed to restore brain activity disrupted by neurodegenerative conditions, representing a fundamentally different approach from traditional pharmaceutical interventions.
Clinical Development and Timeline
The company's HOPE pivotal study is fully enrolled, with top-line data expected later this year. The funding will support this pivotal data readout, regulatory submission to the Food and Drug Administration, and commercial launch preparation ahead of the anticipated 2027 market entry.
Christian Howell, CEO of Cognito Therapeutics (search), emphasized the potential significance of the therapy: "With this financing, we are entering a pivotal moment for our company, and for the patients and families waiting for new options in Alzheimer's disease. Spectris has the potential to become the world's first physician-prescribed, at-home neuroprotective therapy for patients diagnosed with Alzheimer's, designed to preserve cognition and daily function."
Expansion Beyond Alzheimer's
The capital will also help advance the Spectris platform into additional neurodegenerative indications through a network of brain health collaborators, beginning with the WVU Rockefeller Neuroscience Institute (search). This expansion strategy suggests the company sees broader applications for its sensory stimulation approach across multiple neurological conditions.
Gerald Chan, founder of Morningside Ventures (search) and chairman of the board at Cognito, highlighted the therapy's potential to transform treatment delivery: "The therapy has the potential to redefine treatment of a broad category of neurodegenerative diseases by moving care into the home and scaling impact globally."
Market Impact and Accessibility
If successful, Spectris could represent a paradigm shift in Alzheimer's treatment by offering the first physician-prescribed, at-home neuroprotective therapy for the condition. This approach could significantly improve treatment accessibility by eliminating the need for frequent clinical visits and allowing patients to receive therapy in familiar home environments.
The at-home delivery model addresses a critical gap in Alzheimer's care, where patients and families often face significant logistical challenges in accessing specialized treatment centers. Howell noted that the funding "allows us to make this therapy accessible to those who need it most."